University of Kashan Journal of Nanostructures 2251-7871 15 3 2025 07 01 Application of 2,4,6-Trichloro-1,3,5-Triazine (TCT) Supported on Graphene Oxide Nanosheet Decorated with Pd Nanoparticles (Pd/TCT-GO) in Chemotherapy: A Nanocarrier for Mitomycin C and Methotrexate 1278 1290 114985 10.22052/JNS.2025.03.044 EN Yorqinjon Ergashev Tashkent State Technical University, Tashkent, Uzbekistan Nilufar Ruziyeva Bukhara State Pedagogical Institute, Bukhara, Uzbekistan Nilufar Karimova Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan Siddiq Olimov Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan Dilnoza Sagatova Tashkent State Medical University, Tashkent, Uzbekistan Dilfuza Azimova Termez State Pedagogical Institute, Termez, Uzbekistan Khiromon Sirojiddinova Samarkand State Medical University, Samarkand, Uzbekistan Dilshod Kulmuradov Jizzakh Polytechnic Institute, Jizzakh, Uzbekistan Qudrat Bekqulov Chirchik State Pedagogical University, Uzbekistan Mukhlisa Mustafayeva .Mamun University, Khiva, 220900, Uzbekistan Khulkar Sidikova Jizzakh State Pedagogical university, Jizzakh, Uzbekistan Otabek Bobojonov Urgench State University, Urgench, Uzbekistan Bobur Toshbekov Tashkent State University of Economics, Tashkent, Uzbekistan Journal Article 2025 04 24 This study presents the synthesis, characterization, and biomedical application of a novel nanocarrier system, Pd/TCT-GO, designed for targeted chemotherapy. The nanocomposite was prepared through a stepwise process involving the functionalization of graphene oxide (GO) with 2,4,6-trichloro-1,3,5-triazine (TCT) and subsequent decoration with palladium (Pd) nanoparticles. Characterization techniques, including FE-SEM and FT-IR, confirmed the successful synthesis with uniform Pd nanoparticle distribution and effective surface modification. The nanocarrier demonstrated remarkable drug-loading capacities, achieving over 85% encapsulation efficiency for both Mitomycin C and Methotrexate, with sustained release profiles extending up to 48 hours. In vitro studies revealed controlled biphasic drug release, with approximately 85% and 78% of MMC and MTX released, respectively. The multifunctional platform exploits the catalytic activity of Pd and the surface chemistry of TCT and GO, facilitating targeted delivery and controlled release. Comparative analyses highlight its superiority over existing nanocarriers in terms of stability, loading capacity, and release kinetics. Addressing current challenges, future work will focus on improving biocompatibility and targeting efficiency, aiming to translate this promising nanoplatform into clinical oncology applications. https://jns.kashanu.ac.ir/article_114985_0994ccd12482d0d3e6e8aeca41de6ada.pdf